STOCK TITAN

Seer to Participate in the Piper Sandler Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available on the conference website beginning on November 22, 2021. A link to the presentation will also be available on the Investors section of the company’s website at investors.seer.bio.

Seer will be participating in investor meetings at the Piper Sandler Healthcare Conference on Wednesday, December 1, 2021 and Thursday, December 2, 2021.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio


Seer, Inc.

NASDAQ:SEER

SEER Rankings

SEER Latest News

SEER Stock Data

116.89M
46.94M
7.25%
71.38%
4.26%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
REDWOOD CITY

About SEER

seer, inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. the company develops proteograph product suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. it intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. seer, inc. has a collaboration program agreement with discovery life sciences, llc; and commercial agreements with bruker scientific llc and thermo electron north america llc. the company was formerly known as seer biosciences, inc. and changed its name to seer, inc. in july 2018. seer, inc. was incorporated in 2017 and is headquartered in redwood